Short-Interval, Low-Dose [177Lu]Lu–Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma
Stuart More, Thurandie Naiker, Nihaad Jacobs, Ferdinand Oompie, Vikas Prasad
Abstract
ABSTRACT: Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [ 177 Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [ 177 Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.
Topics & Concepts
MedicineGlioblastomaGlutamate carboxypeptidase IIRefractory (planetary science)ProstateProstate-specific antigenProstate cancerNuclear medicineOncologyUrologyInternal medicineCancer researchCancerPhysicsAstrobiologyRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchGlioma Diagnosis and Treatment